Pfizer Exec Says Co’s Research And Development In Oncology Remains Unchanged By Cost-Cut Program

By / / Pfizer

Pfizer Exec Says Co’s Research And Development In Oncology Remains Unchanged By Cost-Cut Program; Starting Negotiations With Payers On U.S. Commercial Prices For Covid Treatment Paxlovid.

Scroll to Top